SYROS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.01 USD | +0.20% |
|
-3.65% | -35.69% |
| Apr. 09 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| Apr. 09 | Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 2.8M | Sales 2025 * | 32.08M | Capitalization | 134M |
|---|---|---|---|---|---|
| Net income 2024 * | -125M | Net income 2025 * | -120M | EV / Sales 2024 * | 47.7 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.17 x |
| P/E ratio 2024 * |
-1.36
x | P/E ratio 2025 * |
-1.5
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.68% |
More Fundamentals
* Assessed data
More news
Latest transcript on Syros Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | -2.91% | ||
| 1 week | -8.09% | ||
| Current month | -7.41% | ||
| 1 month | +11.11% | ||
| 3 months | -29.18% | ||
| 6 months | +67.79% | ||
| Current year | -35.82% |
1 week
4.90
5.34
1 month
4.405.95
Current year
4.408.17
1 year
2.098.17
3 years
2.0970.30
5 years
2.09156.50
10 years
2.09243.75
| Managers | Title | Age | Since |
|---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 17-06-11 | |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 5.01 | +0.20% | 88 047 |
| 24-05-08 | 5 | -2.91% | 75,489 |
| 24-05-07 | 5.15 | +1.38% | 105,559 |
| 24-05-06 | 5.08 | -0.97% | 37,571 |
| 24-05-03 | 5.13 | -1.35% | 95,324 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotes
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5
USD
Average target price
19.25
USD
Spread / Average Target
+285.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.82% | 134M | |
| +22.56% | 46.71B | |
| -1.51% | 41.52B | |
| +48.83% | 41.8B | |
| -3.42% | 29.55B | |
| +10.13% | 25.78B | |
| -20.44% | 19.26B | |
| +26.45% | 11.98B | |
| -0.14% | 12.14B | |
| -0.47% | 12.08B |
- Stock Market
- Equities
- SYRS Stock